These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 15240666)

  • 1. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
    Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
    J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
    Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
    J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
    Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
    J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
    Li B; Allendorf DJ; Hansen R; Marroquin J; Ding C; Cramer DE; Yan J
    J Immunol; 2006 Aug; 177(3):1661-9. PubMed ID: 16849475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
    Vetvicka V; Thornton BP; Ross GD
    J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.
    Yan J; Vetvicka V; Xia Y; Hanikýrová M; Mayadas TN; Ross GD
    Immunopharmacology; 2000 Jan; 46(1):39-54. PubMed ID: 10665778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of beta-glucans on the immune system.
    Akramiene D; Kondrotas A; Didziapetriene J; Kevelaitis E
    Medicina (Kaunas); 2007; 43(8):597-606. PubMed ID: 17895634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
    Thornton BP; Vĕtvicka V; Pitman M; Goldman RC; Ross GD
    J Immunol; 1996 Feb; 156(3):1235-46. PubMed ID: 8558003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.
    Yan J; Allendorf DJ; Brandley B
    Expert Opin Biol Ther; 2005 May; 5(5):691-702. PubMed ID: 15934844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).
    Di Renzo L; Yefenof E; Klein E
    Eur J Immunol; 1991 Jul; 21(7):1755-8. PubMed ID: 2060581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of rat macrophages by Betafectin PGG-glucan requires cross-linking of membrane receptors distinct from complement receptor three (CR3).
    Michalek M; Melican D; Brunke-Reese D; Langevin M; Lemerise K; Galbraith W; Patchen M; Mackin W
    J Leukoc Biol; 1998 Sep; 64(3):337-44. PubMed ID: 9738660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.
    Li B; Cai Y; Qi C; Hansen R; Ding C; Mitchell TC; Yan J
    Clin Cancer Res; 2010 Nov; 16(21):5153-64. PubMed ID: 20855461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.
    Cheung NK; Modak S; Vickers A; Knuckles B
    Cancer Immunol Immunother; 2002 Nov; 51(10):557-64. PubMed ID: 12384807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.
    Allendorf DJ; Yan J; Ross GD; Hansen RD; Baran JT; Subbarao K; Wang L; Haribabu B
    J Immunol; 2005 Jun; 174(11):7050-6. PubMed ID: 15905548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic intervention with complement and beta-glucan in cancer.
    Ross GD; Vetvicka V; Yan J; Xia Y; Vetvicková J
    Immunopharmacology; 1999 May; 42(1-3):61-74. PubMed ID: 10408367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
    Vetvicka V; Thornton BP; Wieman TJ; Ross GD
    J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury.
    Cramer DE; Allendorf DJ; Baran JT; Hansen R; Marroquin J; Li B; Ratajczak J; Ratajczak MZ; Yan J
    Blood; 2006 Jan; 107(2):835-40. PubMed ID: 16179370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans.
    Qi C; Cai Y; Gunn L; Ding C; Li B; Kloecker G; Qian K; Vasilakos J; Saijo S; Iwakura Y; Yannelli JR; Yan J
    Blood; 2011 Jun; 117(25):6825-36. PubMed ID: 21531981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
    Gelderman KA; Lam S; Sier CF; Gorter A
    Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.